In vitro activity of 4'-iodo-4'-deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay.

Abstract

A short-term antimetabolic assay based upon the inhibition of incorporation of nucleic acid precursors was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound doxorubicin (DX) on human colo-rectal carcinoma specimens. IDX showed a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose required to induce a significant antimetabolic effect for IDX was 1/10 that for DX.

• Authors: R Villa, N Zaffaroni, F Giuliani, G Colella, O Sanfilippo, R Silvestrini
• Journal: Investigational new drugs (Invest New Drugs) Vol. 8 Issue 2 Pg. 143-4 (May 1990) ISSN: 0167-6997 [Print] United States
• PMID: 2384300 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 4'-deoxy-4'-iododoxorubicin
• Doxorubicin
• Thymidine
• Uridine

Topics

• Colorectal Neoplasms (metabolism)
• Doxorubicin (analogs & derivatives, pharmacology)
• Humans
• Thymidine (metabolism)
• Tumor Cells, Cultured (drug effects, metabolism)
• Uridine (metabolism)